UK markets closed
  • NIKKEI 225

    29,100.38
    -584.99 (-1.97%)
     
  • HANG SENG

    29,135.73
    +29.58 (+0.10%)
     
  • CRUDE OIL

    62.61
    -0.77 (-1.21%)
     
  • GOLD FUTURES

    1,777.80
    +7.20 (+0.41%)
     
  • DOW

    33,739.34
    -338.29 (-0.99%)
     
  • BTC-GBP

    40,455.87
    +242.95 (+0.60%)
     
  • CMC Crypto 200

    1,283.52
    +49.11 (+3.98%)
     
  • ^IXIC

    13,752.63
    -162.14 (-1.17%)
     
  • ^FTAS

    3,920.05
    -76.60 (-1.92%)
     

Global Cardiovascular Partnering Directory 2014-2020: Company A-Z, Headline Value, Stage of Development at Signing, Deal Component Type, Specific Therapy Target

Research and Markets
·5-min read

Dublin, March 22, 2021 (GLOBE NEWSWIRE) -- The "Global Cardiovascular Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

The Global Cardiovascular Partnering 2014-2020: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 750 cardiovascular deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.

The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Cardiovascular dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Cardiovascular dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Cardiovascular deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Cardiovascular deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Cardiovascular partnering deals by specific Cardiovascular target announced since 2014. The chapter is organized by specific Cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Cardiovascular partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cardiovascular partnering and dealmaking since 2014.

The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cardiovascular technologies and products.

Global Cardiovascular Partnering 2014-2020: Deal trends, players and financials includes:

  • Trends in cardiovascular dealmaking in the biopharma industry since 2014

  • Analysis of cardiovascular deal structure

  • Access to headline, upfront, milestone and royalty data

  • Access to over 750 cardiovascular deal records

  • The leading cardiovascular deals by value since 2014

Available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cardiovascular dealmaking
2.1. Introduction
2.2. Cardiovascular partnering over the years
2.3. Cardiovascular partnering by deal type
2.4. Cardiovascular partnering by industry sector
2.5. Cardiovascular partnering by stage of development
2.6. Cardiovascular partnering by technology type
2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 -Financial deal terms for Cardiovascular partnering
3.1. Introduction
3.2. Disclosed financials terms for Cardiovascular partnering
3.3. Cardiovascular partnering headline values
3.4. Cardiovascular deal upfront payments
3.5. Cardiovascular deal milestone payments
3.6. Cardiovascular royalty rates

Chapter 4 - Leading Cardiovascular deals and dealmakers
4.1. Introduction
4.2. Most active in Cardiovascular partnering
4.3. List of most active dealmakers in Cardiovascular
4.4. Top Cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory
5.1. Introduction
5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Cardiovascular therapeutic target

Appendices
Appendix 1 - Directory of Cardiovascular deals by company A-Z 2014 to 2020
Appendix 2 - Directory of Cardiovascular deals by deal type 2014 to 2020
Appendix 3 - Directory of Cardiovascular deals by stage of development 2014 to 2020
Appendix 4 - Directory of Cardiovascular deals by technology type 2014 to 2020

For more information about this report visit https://www.researchandmarkets.com/r/o3bnbl

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900